Modus Therapeutics Holding AB (publ) (STO:MODTX)
0.3630
-0.0090 (-2.42%)
Oct 14, 2026, 4:50 PM CET
Modus Therapeutics Holding AB Employees
Modus Therapeutics Holding AB had 2 employees as of June 30, 2026. The number of employees did not change compared to the same quarter last year. That makes Modus Therapeutics Holding AB the 43,555th largest employer in the world and 771st in Sweden.
Employees
2
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-8.79M SEK
Market Cap
53.98M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 2 | 0 | - |
| Mar 31, 2026 | 2 | 0 | - |
| Dec 31, 2025 | 2 | 0 | - |
| Sep 30, 2025 | 2 | 0 | - |
| Mar 31, 2025 | 2 | 0 | - |
| Dec 31, 2024 | 2 | 0 | - |
| Sep 30, 2024 | 2 | 0 | - |
| Jun 30, 2024 | 2 | 0 | - |
| Mar 31, 2024 | 2 | 0 | - |
| Dec 31, 2023 | 2 | 0 | - |
| Sep 30, 2023 | 2 | 0 | - |
| Jun 30, 2023 | 2 | 0 | - |
| Mar 31, 2023 | 2 | 0 | - |
| Dec 31, 2022 | 2 | 0 | - |
| Sep 30, 2022 | 2 | 0 | - |
| Jun 30, 2022 | 2 | 0 | - |
| Mar 31, 2022 | 2 | 0 | - |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Nanologica AB | 72 |
| Biovica International AB | 24 |
| NextCell Pharma AB | 24 |
| AcouSort AB | 11 |
| Fluicell AB | 11 |
| Ascelia Pharma AB | 10 |
| Spago Nanomedical AB | 6 |
| Active Biotech AB | 5 |
Modus Therapeutics Holding AB News
- 7 weeks ago - Modus Therapeutics Holding AB Quarterly report: Q2 2026 - Filings
- 4 months ago - Modus Therapeutics Holding AB Quarterly report: Q1 2026 - Filings
- 7 months ago - Modus Therapeutics Holding AB Quarterly report: Q4 2025 - Filings
- 7 months ago - Modus Therapeutics Holding AB Annual report: Q4 2025 - Filings
- 10 months ago - Modus Therapeutics Holding AB Quarterly report: Q3 2025 - Filings